Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.73 |
| ▸ | DRD2 | P14416 | 11/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.73 |
| ▸ | HTR7 | P34969 | 6/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.73 |
| ▸ | DRD1 | P21728 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | DRD5 | P21918 | 2/20 | 0.73 |
| ▸ | HTR1D | P28221 | 2/20 | 0.73 |
| ▸ | HTR1B | P28222 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.73 |
| ▸ | HRH1 | P35367 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.73 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881873 | 0.96 | DRD2 (0.72) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL1961482 | 0.96 | DRD2 (0.72) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL6885578 | 0.95 | DRD2 (0.71) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL6881948 | 0.95 | DRD2 (0.71) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL15489518 | 0.94 | DRD2 (0.74) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL15489540 | 0.93 | HTR2A (0.63) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL19484373 | 0.92 | HTR2A (0.76) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL6851797 | 0.92 | DRD2 (0.70) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL15907985 | 0.92 | DRD2 (0.69) | HTR2ADRD2KCNH2HTR7ADRA2A | |
| SCHEMBL24018542 | 0.91 | DRD2 (0.71) | HTR2ADRD2KCNH2HTR7ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343296-A1 | A process for the purification of paliperidone | Chemo Ibérica, S.A. (ES) | 2011-07-13 | — | — | EP | claimed |
| WO-2011067220-A1 | A PROCESS FOR THE PURIFICATION OF PALIPERIDONE | CHEMO IBÉRICA, S.A. (ES) | 2011-06-09 | — | — | WO | claimed |
| EP-3556759-B1 | HAPTENS OF PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| EP-3556759-B1 | HAPTENS OF PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20190338047-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-3556759-A1 | HAPTENS OF PALIPERIDONE | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556759-A1 | HAPTENS OF PALIPERIDONE | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| US-10370457-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-10370457-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031603-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | ORTHO-CLINICAL DIAGNOSTICS, INC (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2343296-A1 | A process for the purification of paliperidone | Chemo Ibérica, S.A. (ES) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343296-A1 | A process for the purification of paliperidone | Chemo Ibérica, S.A. (ES) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011067220-A1 | A PROCESS FOR THE PURIFICATION OF PALIPERIDONE | CHEMO IBÉRICA, S.A. (ES) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011042450-A1 | CARRIER LINKED PALIPERIDONE PRODRUGS | ASCENDIS PHARMA AS (DK) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042453-A1 | SUBCUTANEOUS PALIPERIDONE COMPOSITION | ASCENDIS PHARMA AS (DK) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | LY96, OPRL1, HTR3C | HTR2A 33/4885DRD2 380/4885KCNH2 2524/4885 |
| US-10370457-B2 | Antibodies to paliperidone haptens and use thereof | LY96, OPRL1, HTR3C | HTR2A 33/4885DRD2 380/4885KCNH2 2524/4885 |
| US-20190338047-A1 | Antibodies to Paliperidone Haptens and Use Thereof | LY96, OPRL1, HTR3C | HTR2A 33/4885DRD2 380/4885KCNH2 2524/4885 |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | LY96, OPRL1, HTR3C | HTR2A 33/4885DRD2 380/4885KCNH2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.